A clinical review of Proviron (mesterolone), the oral DHT-derivative androgen not approved in the US, including its pharmacology, evidence gaps, and how it compares to testosterone cypionate, enanthate, propionate, and pellet therapy.
A clinical guide to the testosterone patch (Androderm), comparing transdermal TRT delivery with testosterone cypionate, enanthate, propionate, and pellets for treating male hypogonadism.
Evidence-based analysis of how testosterone replacement therapy (TRT) affects benign prostatic hyperplasia (BPH), including prostate volume data, LUTS scores, and monitoring protocols.
Testosterone replacement therapy suppresses sperm production in most men. Learn the mechanism, timeline, recovery options, and fertility-preserving alternatives backed by clinical evidence.
Does testosterone replacement therapy cause prostate cancer? A detailed review of clinical trials, guidelines, and monitoring protocols for men on TRT.
A complete breakdown of hormone replacement therapy costs without insurance in 2026, covering TRT, estrogen therapy, peptides, and GLP-1 medications with real pricing data and cost-saving strategies.
A guide to purchasing testosterone pills online safely, covering FDA-approved formulations, legitimate telehealth platforms, red flags for counterfeit products, and legal requirements for testosterone prescriptions.
Learn how to safely order testosterone online through licensed telehealth platforms, what to look for in a legitimate provider, required lab work, and red flags to avoid.
Vitamin D affects testosterone, bone density, immune function, and mood. Learn the evidence-based doses, optimal blood levels, and clinical data behind vitamin D supplementation for men.
Clitoral stimulation remains the primary orgasm pathway for most women during and after menopause. Learn how hormonal changes affect clitoral anatomy, sensation, and what treatments can help.
Estrogen decline, insulin resistance, muscle loss, and cortisol shifts drive perimenopausal weight gain. Learn the hormonal mechanisms, clinical evidence, and physician-backed strategies to manage body composition changes.
Bioidentical hormone therapy for men uses lab-synthesized hormones structurally identical to endogenous testosterone. Learn about FDA-approved options, dosing, risks, and monitoring.
Learn where to get testosterone replacement therapy (TRT) legally and safely, including telehealth clinics, urologists, endocrinologists, and compounding pharmacies.
Testosterone pellets deliver a fixed, non-adjustable dose of testosterone that commonly produces male-range blood levels in women. Here is what is established, what is plausible but unproven, and what alternatives have better evidence.
Metformin costs $4-$20/month generic; Januvia runs $450-$550 branded. Metformin also has stronger long-term outcomes data, per major guidelines.
How to dose metformin safely in adults 65 and older. Covers renal-adjusted starting doses, titration schedules, eGFR thresholds, B12 monitoring, and deprescribing criteria backed by primary-source evidence.
Evidence-based monitoring guide for metformin in adults 65 and older. Covers renal function tracking, B12 screening, lactic acidosis risk, deprescribing criteria, and recommended lab intervals.
Find out whether Humana covers metformin for type 2 diabetes and off-label uses, which formulary tier it sits on, prior-authorization rules, and how to appeal a denial.
A physician-level breakdown of how metformin works, from mitochondrial Complex I inhibition and AMPK activation to hepatic glucose suppression, gut signaling, and microbiome remodeling.
Missing one metformin dose usually causes only a modest fasting glucose rise of 15 to 30 mg/dL, not a crisis. Never double up; repeated gaps raise HbA1c.
A detailed history of metformin patents, generic approvals, extended-release formulations, and the current competitive field for the world's most prescribed diabetes drug.
Metformin and vitamin B12 deficiency: DPPOS found 4.3% deficiency vs 2.3% placebo; ADA advises periodic B12 checks. FDA boxed warning: lactic acidosis.
Clinical protocols for switching between metformin and other glucose-lowering drugs, including GLP-1 agonists, SGLT2 inhibitors, sulfonylureas, and insulin. Covers timing, dose bridging, and monitoring.
Evidence-based guide to safely discontinuing methimazole (Tapazole) for hyperthyroidism and Graves' disease, including taper schedules, lab monitoring, relapse predictors, and when definitive therapy may be preferred.
Miss a methimazole dose? Take it when you remember unless your next dose is under 4 hours away, then skip it. Never double up; one lapse rarely spikes T4.
A clinical deep-dive into methimazole (Tapazole) ADME pharmacokinetics, including bioavailability, thyroid gland concentration, hepatic metabolism, renal elimination, and dose-response implications for hyperthyroidism treatment.
Evidence-based guide to methimazole use during pregnancy and breastfeeding, including first-trimester teratogenicity risks, PTU switching protocols, and lactation compatibility data.
A clinical review of methimazole safety signals, FDA warnings, boxed label changes, and post-market adverse event data for hyperthyroidism and Graves disease treatment.
Complete guide to methimazole (Tapazole) monitoring in young adults aged 18-29. Covers CBC, liver function, thyroid panels, fertility considerations, and when to call your doctor.
A clinical comparison of MK-677 pricing against prescription GH secretagogues, injectable somatropin, and compounded peptide alternatives, with efficacy and safety data for each option.
Evidence-based monitoring protocol for MK-677 (ibutamoren) use in adults 65 and older, covering IGF-1 tracking, glucose surveillance, edema assessment, and drug interaction screening.
A clinical history of MK-677 (ibutamoren mesylate), from Merck's 1990s discovery program through Phase II trials, including its mechanism as an oral ghrelin receptor agonist and the research that shaped growth hormone secretagogue science.
Evidence-based monitoring schedule for MK-677 (ibutamoren) including IGF-1, fasting glucose, HbA1c, insulin, prolactin, and recommended exam intervals.
A clinician-grade review of MK-677 (ibutamoren) off-label applications, including body composition, bone density, sleep quality, and sarcopenia, graded by strength of evidence from published trials.
A clinical review of MK-677 (ibutamoren) safety data for adults aged 50-64, covering insulin resistance, edema, cardiovascular risk, and GH/IGF-1 monitoring.
A clinical deep dive into how polymorphisms in GHSR, GH1, IGF1, and CYP3A4 genes influence MK-677 (ibutamoren) efficacy, side-effect burden, and dosing considerations.
Evidence-based guide to MK-677 (ibutamoren) storage conditions, chemical stability, degradation pathways, and shelf life. Covers temperature, light, humidity, and reconstitution handling.
Clinical guidance on transitioning between MK-677 (ibutamoren) and other growth hormone secretagogues, including washout periods, IGF-1 monitoring, and protocol considerations.
A study-arm replay for ibutamoren in young adults, showing why experimental doses, durations, and timing do not establish a recommended clinical regimen.
Modafinil induces CYP3A4 and inhibits CYP2C19, lowering birth control and cyclosporine efficacy while raising levels of omeprazole, diazepam, and phenytoin.
A physician-level breakdown of how modafinil (Provigil) works, covering dopamine transporter inhibition, norepinephrine reuptake, histaminergic activation, orexin signaling, and GABA-glutamate modulation with full PubMed citations.
Evidence-based monitoring guide for MOTS-c mitochondrial peptide in adults 65 and older. Covers baseline labs, renal function tracking, glucose surveillance, drug interaction screening, and deprescribing considerations.
Evidence-based guide to MOTS-c mitochondrial peptide dosing considerations in patients with hepatic impairment, covering mechanism, pharmacokinetics, safety, and clinical guidance.
Evidence-based monitoring guide for MOTS-c mitochondrial peptide use in adults aged 50 to 64, covering baseline labs, ongoing safety markers, cardiovascular risk, and metabolic tracking.
A clinical review of MOTS-c mitochondrial peptide intellectual property, patent filings, regulatory status, and projected generic availability for metabolic and longevity applications.
MOTS-c is an investigational mitochondrial peptide with no human pregnancy or lactation data. Learn what preclinical research reveals and why clinicians advise against use during pregnancy and breastfeeding.
MOTS-c is not approved by the FDA, EMA, Health Canada, or MHRA. Learn the current regulatory status of this mitochondrial-derived peptide across major markets, what the science shows, and what that means for clinical access.
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 30-49. Covers the full titration schedule from 2.5 mg to 15 mg, injection technique, missed-dose rules, and age-specific clinical considerations.
Aetna (CVS Health) covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and how to reduce out-of-pocket costs.
Anthem (Elevance Health) covers Mounjaro for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and cost-saving options.
Find out whether Cigna covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including prior authorization criteria, formulary placement, step therapy rules, and how to appeal a denial.
Mounjaro costs about $1,023 monthly without insurance, similar to Ozempic but pricier than Trulicity. See coverage options and how efficacy compares.
Find out whether Humana covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including formulary placement, prior-authorization criteria, step therapy rules, and how to appeal a denial.
Kaiser Permanente coverage for Mounjaro (tirzepatide) explained: formulary status, prior authorization criteria, step therapy requirements, manufacturer savings card rules, and how to appeal a denial.
A clinical deep-dive into tirzepatide (Mounjaro) manufacturing processes, supply chain disruptions, FDA shortage listings, and Eli Lilly's capacity expansion timeline.
State Medicaid coverage for Mounjaro (tirzepatide) varies widely. Learn which states cover it for type 2 diabetes vs. weight loss, prior authorization requirements, step therapy rules, and how to appeal a denial.
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 50-64. Covers titration schedule, dose adjustments for kidney function and polypharmacy, and clinical trial data from SURPASS trials.
Evidence-based guide to tirzepatide (Mounjaro) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and what remains unknown.
Mounjaro is FDA-approved (May 2022) for type 2 diabetes, plus approved by EMA, MHRA, and Health Canada. See exact approval dates by country.
A clinician-grade review of tirzepatide (Mounjaro) safety signals, FDA black box warnings, postmarket adverse events, label revisions, and what prescribers should monitor.